1-6 of 6
Stephen T. Keir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas

Shiyou Wei, Delong Yin, Shengnan Yu, Xiang Lin, Milan R. Savani, Kuang Du, Yin Ku, Di Wu, Shasha Li, Hao Liu, Meng Tian, Yaohui Chen, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Stephen T. Keir, Eric T. Sugarman, Rebecca A. Deek, Marilyne Labrie, Mustafa Khasraw, Yiling Lu, Gordon B. Mills, Meenhard Herlyn, Kongming Wu, Lunxu Liu, Zhi Wei, Keith T. Flaherty, Kalil Abdullah, Gao Zhang, David M. Ashley
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2180–2195.
https://doi.org/10.1158/1078-0432.CCR-21-0833
Published: 13 May 2022
View articletitled, Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Open the PDF for Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas in another window
Includes: Supplementary data
Journal Articles

A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

Shengnan Yu, Shiyou Wei, Milan Savani, Xiang Lin, Kuang Du, Ilgen Mender, Silvia Siteni, Themistoklis Vasilopoulos, Zachary J. Reitman, Yin Ku, Di Wu, Hao Liu, Meng Tian, Yaohui Chen, Marilyne Labrie, Casey M. Charbonneau, Eric Sugarman, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Wen Jiang, Roger E. McLendon, Edward Pan, Mustafa Khasraw, Kyle M. Walsh, Yiling Lu, Meenhard Herlyn, Gordon Mills, Utz Herbig, Zhi Wei, Stephen T. Keir, Keith Flaherty, Lunxu Liu, Kongming Wu, Jerry W. Shay, Kalil Abdullah, Gao Zhang, David M. Ashley
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6800–6814.
https://doi.org/10.1158/1078-0432.CCR-21-0374
Published: 15 December 2021
View articletitled, A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas
Open the PDF for A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas in another window
Includes: Supplementary data
Journal Articles

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma

Patrick C. Gedeon, Teilo H. Schaller, Satish K. Chitneni, Bryan D. Choi, Chien-Tsun Kuan, Carter M. Suryadevara, David J. Snyder, Robert J. Schmittling, Scott E. Szafranski, Xiuyu Cui, Patrick N. Healy, James E. Herndon, II, Roger E. McLendon, Stephen T. Keir, Gary E. Archer, Elizabeth A. Reap, Luis Sanchez-Perez, Darell D. Bigner, John H. Sampson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3611–3631.
https://doi.org/10.1158/1078-0432.CCR-17-0126
Published: 31 July 2018
View articletitled, A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
Open the PDF for A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma in another window
Includes: Supplementary data
Journal Articles

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Gorlick, Hernan Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 819–832.
https://doi.org/10.1158/1078-0432.CCR-14-2572
Published: 16 February 2015
View articletitled, Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Open the PDF for Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program in another window
Includes: Supplementary data
Journal Articles

Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy

Vidyalakshmi Chandramohan, Xuhui Bao, Stephen T. Keir, Charles N. Pegram, Scott E. Szafranski, Hailan Piao, Carol J. Wikstrand, Roger E. McLendon, Chien-Tsun Kuan, Ira H. Pastan, Darell D. Bigner
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4717–4727.
https://doi.org/10.1158/1078-0432.CCR-12-3891
Published: 02 September 2013
View articletitled, Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy
Open the PDF for Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy in another window
Includes: Supplementary data
Journal Articles

ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors

Jeremy N. Rich, Sith Sathornsumetee, Stephen T. Keir, Mark W. Kieran, Andrea Laforme, Arja Kaipainen, Roger E. McLendon, Michael W. Graner, B.K. Ahmed Rasheed, Ling Wang, David A. Reardon, Anderson J. Ryan, Catherine Wheeler, Isaiah Dimery, Darell D. Bigner, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (22): 8145–8157.
https://doi.org/10.1158/1078-0432.CCR-05-0319
Published: 18 November 2005
View articletitled, ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors
Open the PDF for ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors in another window